RecruitingNCT02302742
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations
Sponsor
University of Kansas Medical Center
Enrollment
1,500 participants
Start Date
Mar 22, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Eligibility
Inclusion Criteria13
- Triple Negative Breast Cancer
- ER/PR \<10% and HER negative per current ASCO/CAP guidelines
- Stages I-IV
- Any age at diagnosis
- Patient must be within 5 years of diagnosis
- Eligible regardless of genetic testing status
- Genetic testing recommended for patients meeting NCCN and Medicare guidelines
- AND/OR
- Germline mutation Carriers
- Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer
- Healthy patients harboring mutations also eligible
- There is no time limit from the time of diagnosis of cancer and enrollment.
- Eligible regardless of personal history of cancer
Exclusion Criteria3
- Triple Negative Breast Cancer -Patient is not within five years of diagnosis
- Germline mutation Carriers:
- Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02302742
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location